comparemela.com

Latest Breaking News On - Joyce allaire - Page 20 : comparemela.com

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024

Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies

United statesSan antonioJim murrayJyun wangNishant dwivediMonzrm al malkiJoyce allaireDebora bartonHyungc suhGavin macbeathNina abelowitzUdayr popatHenryb gonzHeather savelleShrikanta chattopadhyayErica buonomo

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today

United kingdomLong island jewish medical centerNew yorkUnited statesJonathan barrattJoyce allaireRichard lafayetteMari purpuraStanford university department of medicineNephrology at stanford universityCommunications committeeStanford glomerular disease centerRenal research groupGlomerular disease advisory committeeAmerican society of nephrologyLotte new york palace hotel

Vera Therapeutics Announces Appointment of Industry

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and.

Stanford universityUnited statesJoyce allaireOrionis biosciencesCelia linMarshall fordyceWilliamd turnerMari purpuraRobertm brennerJohns hopkins universityGlobal quality at dynavax technologies corporationVera therapeutics incCalifornia state university at long beachAlbert einstein college of medicineRegulatory affairsSierra oncology inc

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively

United statesJoyce allairePatricia carlosLauren barbieroEdwinj tuckerScott brunAlex grayRonald martellEuropean union orphan drug designationRegulatory affairs qualityEuropean medicines agencyAmerica society of hematologyCompany clinical trial applicationsJasper therapeutics incClinical trial applicationsChief executive officer

Jasper Therapeutics Highlights Recent Accomplishments and

- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase.

United statesRonald martellAlex grayPatricia carlosJoyce allaireLauren barbieroScott brunEdwinj tuckerCompany clinical trial applicationsRegulatory affairs qualityJasper therapeutics incAmerica society of hematologyEuropean union orphan drug designationEuropean medicines agencyClinical trial applicationsChief executive officer

vimarsana © 2020. All Rights Reserved.